UBS Group’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

UBS Group’s Portfolio BIOSU Stock Details BIOSU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50	Closed	-$542	–	10546
2023 Q3	$542	Buy	+50	New	+$540	﹤0.01%	8418
2022 Q3	–	Sell	-91	Closed	-$1K	–	11315
2022 Q2	$1K	Sell	91 -11	-11%	-$110	﹤0.01%	10090
2022 Q1	$1K	Sell	102 -27,000	-100%	-$270K	﹤0.01%	10029
2021 Q4	$271K	Buy	+27,102	New	+$271K	﹤0.01%	5444

UBS Group's BIOSU Position: Q4 2023 in Review

UBS Group sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q4 2023, closing a stake of 50 shares — an estimated $542 sold.

UBS Group first reported a position in BIOSU in Q4 2021 and held it in 4 quarters. The position peaked at $271K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOSU as of Q4 2023.

UBS Group reported no remaining BioPlus Acquisition Corp. Unit position as of Q4 2023 after selling out during the quarter.
UBS Group sold 50 BioPlus Acquisition Corp. Unit shares in Q4 2023, an estimated $542.
UBS Group first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
UBS Group's BioPlus Acquisition Corp. Unit position peaked at $271K in Q4 2021.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.